EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR, ALLOSTERIC BINDING INHIBITOR Russian patent published in 2016 - IPC C07K14/71 G01N33/566 

FIELD: biotechnology.

SUBSTANCE: present invention relates to biotechnology, more specifically to extracellular binding domain for allosteric inhibitor and can be used for identification of such inhibitors. Wherein allosteric FGFR inhibitor is identified, if in presence of ligand binding with receptor ligand-binding domain at least one underlying FGFR pathway is inhibited, while at least one other underlying pathway remains unchanged.

EFFECT: invention enables identification of low-molecular allosteric FGFR inhibitor at comparison of changes of states, preferably, in gene induction or phosphorylation of, at least, one reporter for, at least, two different underlying signal pathways, dependent on activation/inhibiting of said tyrosine kinase receptor, preferably selected from ERK1/2 signalling pathway, PLCγ signal pathway and ACT signalling pathway.

3 cl, 21 dwg, 12 ex